Docosahexaenoic Acid Supplementation in Postnatal Growth Restricted Rats Does Not Normalize Lung Function or PPARγ...

Area of Science:

• Neonatal physiology
• Pulmonary medicine
• Nutritional science

Background:

• Bronchopulmonary dysplasia (BPD) is a common complication in preterm neonates, often linked to poor growth and nutritional deficits.
• Docosahexaenoic acid (DHA) supplementation has been investigated for BPD, but recent trials suggest potential harm in specific subgroups.
• Altered fatty acid profiles and aberrant expression of peroxisome proliferator-activated receptor gamma (PPARγ) are implicated in poor lung outcomes.

Purpose of the Study:

• To investigate the effects of DHA supplementation on lung outcomes in a rat model of postnatal growth restriction (PGR).
• To determine if DHA alters circulating lipid profiles, lung mechanics, and PPARγ variant expression in PGR rat pups.
• To assess the expression of the PPARγ splice variant, PPARγΔ5, in the developing rat lung.

Main Methods:

• Utilized a previously established rat model of postnatal growth restriction (PGR).
• Administered DHA supplementation to PGR rat pups.
• Assessed circulating lipid profiles, lung mechanics, and PPARγ variant expression (including PPARγΔ5).

Main Results:

• The PPARγ splice variant, PPARγΔ5, was confirmed to be expressed in the developing rat lung.
• DHA supplementation in PGR rat pups altered global circulating fatty-acid profiles.
• DHA supplementation did not normalize the impaired lung mechanics or altered PPARγ activity associated with PGR.

Conclusions:

• PPARγΔ5 is present in the developing rat lung and may play a role in lung development.
• DHA supplementation in the context of growth restriction does not improve lung function and alters systemic fatty acid metabolism.
• Further research is needed to understand the complex interactions between fatty acids, PPARγ, and lung development in preterm neonates.